From Food Wholesaler to Pharma Giant: The Rise and Controversies of Cardinal Health

In this episode, we explore the massive footprint of Cardinal Health, a company that began in 1971 as a simple food wholesaler in Ohio before pivoting to become the 15th highest revenue-generating company in the United States. We trace the aggressive growth strategy led by founder Robert D. Walter, moving from the acquisition of Bailey Drug Company in 1979 to the multi-billion dollar purchases of Pyxis, Medtronic’s patient care portfolio, and a recent stake in Solaris Health.

We also examine the significant legal and ethical challenges the company has faced, specifically its role in the U.S. opioid epidemic. We discuss the DEA investigations that labeled the company’s distribution practices an "imminent danger to the public," resulting in facility suspensions and a massive $6.4 billion settlement agreement finalized in 2021. Join us as we break down how this distributor provides medical products to over 75% of U.S. hospitals while navigating decades of regulatory scrutiny.

Key Topics Covered:

• The Pivot: How Cardinal Foods sold its operations to become a pharmaceutical powerhouse.
• Strategic Expansion: Major acquisitions including Cordis, Kinray, and the Red Oak Sourcing venture with CVS.
• The Opioid Crisis: Details on the $26 billion settlement involving Cardinal, McKesson, and AmerisourceBergen, and specific lawsuits from the State of Oklahoma and the City of Baltimore.
• Regulatory Clashes: FDA seizures of Alaris SE infusion pumps and DEA suspensions of distribution centers in Florida and New Jersey.
• Modern Era: Recent moves into at-home solutions with the acquisition of the Advanced Diabetes Supply Group.

To visualize Cardinal Health's role in the medical world, think of the company as the massive circulatory system of the American healthcare body: it is essential for pumping vital supplies to over 100,000 locations, but when that system fails to filter out toxins—like excessive opioids—the entire body suffers the consequences.